Gene therapy trial offers hope for rare Blindness-Causing eye disease
NCT ID NCT07406854
First seen Feb 13, 2026 · Last updated May 12, 2026 · Updated 12 times
Summary
This study tests a gene therapy called NR082 for Leber's hereditary optic neuropathy (LHON), a rare inherited eye disease that leads to vision loss. About 95 people aged 12 to 75 with a specific gene mutation (ND4) and vision problems lasting 6 months to 10 years will receive a single injection into each eye or a sham procedure. The goal is to see if the treatment safely improves eyesight over 52 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEBER HEREDITARY OPTIC NEUROPATHY (LHON) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.